尔康制药(300267) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥353,547,866.17, representing a 28.19% increase compared to ¥275,789,340.20 in the same period last year[4] - Net profit attributable to shareholders reached ¥28,112,585.22, a significant increase of 868.91% from ¥2,901,461.74 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥24,709,317.94, up 839.24% from a loss of ¥3,342,539.14 in the previous year[4] - The company's basic earnings per share rose to ¥0.0136, an increase of 871.43% compared to ¥0.0014 in the same period last year[4] - Total operating revenue for the current period reached ¥353,547,866.17, a significant increase of 28.1% compared to ¥275,789,340.20 in the previous period[19] - Net profit attributable to the parent company was ¥28,112,585.22, compared to ¥2,901,461.74 in the previous period, marking a substantial increase[20] - Operating profit for the current period was ¥26,228,298.64, up from ¥838,832.93 in the previous period, indicating strong operational performance[20] - The company reported a total comprehensive income of ¥12,391,421.98, compared to -¥34,221,597.97 in the previous period, showing a recovery in overall performance[20] - The basic and diluted earnings per share were both ¥0.0136, up from ¥0.0014 in the previous period, indicating improved profitability[20] Cash Flow and Assets - The net cash flow from operating activities was negative at -¥4,148,506.90, a decline of 138.77% compared to ¥10,699,220.82 in the same period last year[4] - Cash and cash equivalents at the end of the period totaled ¥497,470,142.04, an increase from ¥469,743,222.10 at the end of the previous period[24] - The company's cash and cash equivalents decreased to RMB 686,061,848.21 from RMB 698,537,949.74[17] - The total assets at the end of the reporting period were ¥5,124,329,676.91, a decrease of 1.45% from ¥5,199,734,491.19 at the end of the previous year[4] - Total liabilities and equity amounted to ¥5,124,329,676.91, a decrease from ¥5,199,734,491.19 in the previous period[19] Investments and Expenses - The company's investment income increased by 715.04% to ¥266.11 from ¥32.65 in the previous year, mainly due to higher returns from financial product investments[11] - The cash flow from investing activities improved significantly, with a net inflow of ¥7,337.05 compared to a net outflow of -¥20,063.45 in the same period last year, marking a 136.57% increase[12] - The company experienced a 67.97% reduction in selling expenses, which decreased to ¥812.86 from ¥2,537.79 year-on-year, primarily due to lower promotional costs[10] - Research and development expenses increased to ¥9,935,801.85 from ¥8,851,765.51, reflecting the company's commitment to innovation[19] Accounts and Liabilities - The company reported a significant increase in accounts receivable, which rose by 36.51% to ¥14,085.59 from ¥10,318.19 year-on-year, attributed to increased sales revenue[9] - The company's accounts receivable increased to RMB 140,855,852.22 from RMB 103,181,869.28[17] - Total liabilities decreased to RMB 709,570,569.44 from RMB 797,540,680.70[18] - Short-term borrowings decreased to RMB 401,261,527.78 from RMB 488,198,472.23[18] - The total non-current assets decreased to RMB 3,447,614,260.36 from RMB 3,482,652,834.83[18] - The company's retained earnings increased to RMB 1,194,203,400.81 from RMB 1,166,090,815.59[18] Subsidiaries and New Ventures - The company established a wholly-owned subsidiary, Hunan Guanha Technology Co., Ltd., with a registered capital of RMB 10 million to focus on new productivity investments[15] - The company's subsidiary in Nigeria, Erkang Mining, achieved a new operating income of RMB 77.2749 million during the reporting period[15] Other Information - The first quarter report has not been audited[25] - The new accounting standards will be implemented starting in 2025[25]